Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy Response
CancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.
Potential Clinical Implications of ctDNA as a Predictive Biomarker
George Ansstas, MD, and Firas B. Badin, MD, discuss the potential clinical implications of using circulating tumor DNA as a predictive biomarker in solid tumor patients treated with immunotherapy.
ctDNA as a Predictive Biomarker in Patients Treated with Pembrolizumab
Two medical oncologists summarize data on use of circulating tumor DNA as a predictive biomarker in solid tumor patients treated with pembrolizumab.